ライフサイエンスコーパス: neurotensin receptor

1 r loop, and transmembrane VII regions of the neurotensin receptor.

2 a nonpeptide antagonist of the high-affinity neurotensin receptor (0.25 or 2.5 microgram, i.c.v., or

3 groups were inherently detrimental to human neurotensin receptor 1 (hNTR1) binding affinity or recep

4 peutic efficacy of oAd/DCN/LRP-PEG-NT toward neurotensin receptor 1 (NTR)-overexpressing pancreatic c

5 cally induced hypothermia (PIH) by the novel neurotensin receptor 1 (NTR1) agonist ABS-201 in a focal

6 mbinations that preferentially interact with neurotensin receptor 1 (NTR1) and our stabilized mutants

7 2-carboxylic acid (SR48692), a high-affinity neurotensin receptor 1 (NTR1) antagonist.

8 Using neurotensin receptor 1 (NTR1) as a proof of principle, w

9 In this study, we define the high-affinity neurotensin receptor 1 (NTR1) as a tractable new molecul

10 Increased expression of neurotensin receptor 1 (NTR1) has been shown in a large

11 Neurotensin (NT) and neurotensin receptor 1 (NTR1) have been shown to play a

12 Neurotensin receptor 1 (NTR1) is overexpressed in ductal

13 tivating the G protein-coupled receptor, the neurotensin receptor 1 (NTR1).

14 quired for this network disturbance, we used neurotensin receptor 1 (Ntsr1) cre-driver mice to ablate

15 STR1, SSTR2), kisspeptin recepotor (KissR1), neurotensin receptor 1 (NTSR1), neuropeptide S receptor

16 ese effects requires mast cell expression of neurotensin receptor 1 and neurolysin.

17 Starting from the rat neurotensin receptor 1, a class A GPCR, we generated a s

18 receptors (angiotensin II type 1A receptor, neurotensin receptor 1, vasopressin V2 receptor, thyrotr

19 Compound 1 binds to human neurotensin receptors 1 and 2 with IC(50) of 10.6 and 54

20 of the GHS-R is most closely related to the neurotensin receptor-1 (NT-R1) (35% overall protein iden

21 Neurotensin receptor-1 (NTR1) is a promising target for

22 on by binding of its high affinity receptor, neurotensin receptor-1 (NTR1).

23 Pharmacological manipulation of neurotensin receptor 2 confirms behavioural effects obse

24 acrophage inflammatory protein 1 (MIP-1) and neurotensin receptor 2.

25 te as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy

26 ta further support a role for NT69L or other neurotensin receptor agonists to treat nicotine addictio

27 tained high affinity and agonist potency for neurotensin receptors and exhibited dramatically improve

28 ural elements for species specificity of the neurotensin receptors, and may expedite developing nonpe

29 ither the protein phosphatase calcineurin or neurotensin receptors, and persists surprisingly long af

30 otensin analogs, biological functions of the neurotensin receptors, and structural elements for speci

31 eadministration of a mu opioid receptor or a neurotensin receptor antagonist into the ventral PAG.

32 Pretreatment of rats with the neurotensin receptor antagonist SR-48, 692 inhibits toxi

33 r to be the high-affinity receptor since the neurotensin receptor antagonist SR48692, when given i.c.

34 wo new tritiated tracers for angiotensin and neurotensin receptors are described.

35 administered peripherally, serum levels and neurotensin receptor binding potency of 1 peaked within

36 e a basis for rationalizing mutations of the neurotensin receptor gene but also offer insights into u

37 e constructed a series of chimeric rat/human neurotensin receptor genes and expressed them by transie

38 High-affinity neurotensin receptors in the periphery appear to play a

39 Ca2+ mobilization mediated by neurotensin receptors is also inhibited by ET-18-OCH3.

40 he C-terminal region of NT1-13 recognized by neurotensin receptors, modulate distension-induced relea

41 roscopic immunolabeling of the high-affinity neurotensin receptor (NTR) and neurotensin in these subd

42 the present study, we have cloned the human neurotensin receptor (NTR) gene, determined its structur

43 The prevalence of neurotensin receptor (NTR) in several human tumors makes

44 To date, there are two types of the neurotensin receptor (NTR) that have been molecularly cl

45 1AR), endothelin type A receptor (ETAR), and neurotensin receptor (NTR).

46 e promoter region of the mouse high affinity neurotensin receptor (Ntr-1) gene was characterized, and

47 Accumulating evidence suggests that neurotensin receptors (NTRs) play key roles in cancer gr

48 l and hydrodynamic experiments that purified neurotensin receptor NTS1, a class A GPCR, dimerizes in

49 The type 1 neurotensin receptor (NTS1) belongs to the G protein-cou

50 Compounds active at neurotensin receptors (NTS1 and NTS2) exert analgesic ef

51 We previously determined the structure of neurotensin receptor NTSR1 in an active-like conformatio

52 and a hormone through the activation of the neurotensin receptor NTSR1, a G-protein-coupled receptor

53 re of a constitutively active, agonist-bound neurotensin receptor (NTSR1) and molecular dynamics simu

54 opeptide growth factor, and its two specific neurotensin receptors, NTSR1 and NTSR2, were shown to be

55 (AS-MOR MM), antisense PNAs targeted to the neurotensin receptor subtype 1 (AS-NTR1), or saline and

56 ur results led us to propose a region of the neurotensin receptor that may be involved in determining

57 ding only to microspots corresponding to the neurotensin receptor; this specificity was further demon

58 pitates with G(alpha)q/11 upon activation of neurotensin receptors; this association is inhibited by

59 c pocket on the extracellular surface of the neurotensin receptor to accommodate its ligands apparent

60 in-G were found to be potent agonists of rat neurotensin receptor type 1.

61 Compounds acting via the neurotensin receptor type 2 (NTS2) are known to be activ

62 cosylated Thr10 contulakin-G for a number of neurotensin receptor types including the human neurotens

63 Neurotensin receptor was expressed in 88% of the surgica

64 the observed Kd values at the rat and human neurotensin receptors were 0.046 and 5.8 nM, respectivel